TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Genenta Science SpA Sponsored ADR ( (GNTA) ) just unveiled an announcement.
On December 30, 2024, Genenta Science S.p.A. and AGC Biologics S.p.A. amended their Development and Master Services Agreement, originally effective from March 6, 2019. This amendment included a work statement for AGC to manufacture and test Genenta’s cell therapy products in a dedicated GMP suite. However, on August 1, 2025, Genenta notified AGC of its decision to terminate this work statement, effective August 1, 2026, which will end the commitment to a dedicated suite while allowing AGC to continue manufacturing in shared suites. This decision reflects a strategic shift in Genenta’s operational commitments and may impact its production processes and collaboration dynamics with AGC.
The most recent analyst rating on (GNTA) stock is a Buy with a $25.00 price target. To see the full list of analyst forecasts on Genenta Science SpA Sponsored ADR stock, see the GNTA Stock Forecast page.
More about Genenta Science SpA Sponsored ADR
Genenta Science S.p.A. operates in the biotechnology industry, focusing on the development of cell therapy products. The company is engaged in innovative therapies aimed at treating various diseases, leveraging advanced biotechnological processes.
Average Trading Volume: 13,102
Technical Sentiment Signal: Hold
Current Market Cap: $70.34M
For an in-depth examination of GNTA stock, go to TipRanks’ Overview page.